Melanoma (Skin Cancer)
54
27
30
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 54 trials
100.0%
+13.5% vs benchmark
4%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (54)
A Comparative Usability Study of Two Total Body Skin Imaging Systems
Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
SL-28 for Advanced Solid Tumours
Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
MELanoma Brain Metastasis Treated With CYberknife
Investigating Real-Time Immunotherapy Symptoms Study
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
Digital Phenotyping of Psychological Distress in Skin Cancer Patients
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma
A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure
Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers